In vitro killing of Escherichia coli, Staphylococcus pseudintermedius and Pseudomonas aeruginosa by enrofloxacin in combination with its active metabolite ciprofloxacin using clinically relevant drug concentrations in the dog and cat

Veterinary Microbiology

Volumn 155, Issue 2-4, 2012, Pages 284-290

  Blondeau, J M ^a,b,c   Borsos, S ^a   Blondeau, L D ^a   Blondeau, B J ^a  

^a ROYAL UNIVERSITY HOSPITAL   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Enrofloxacin; Escherichia coli; Killing; Pseudomonas aeruginosa; Staphylococcus pseudintermedius

Indexed keywords

CIPROFLOXACIN; ENROFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CAT; DOG; DRUG POTENTIATION; ESCHERICHIA COLI; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

ANIMALS; ANTI-BACTERIAL AGENTS; CATS; CIPROFLOXACIN; DOGS; ESCHERICHIA COLI; FLUOROQUINOLONES; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS;

ANIMALIA; CANIS FAMILIARIS; ESCHERICHIA COLI; NEGIBACTERIA; POSIBACTERIA; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS PSEUDINTERMEDIUS;

EID: 84857038190     PISSN: 03781135     EISSN: 18732542     Source Type: Journal    
DOI: 10.1016/j.vetmic.2011.08.015     Document Type: Article

References (22)

1. Blondeau J.M. Expanded activity and utility of the new fluoroquinolones: a review. Clin. Ther. 1999, 21:3-40.
2. Blondeau J.M. New concepts in antimicrobial susceptibility testing: the mutant prevention concentration and mutant selection window approach. Vet. Dermatol. 2009, 20:383-396.
3. Blondeau J.M., Hansen G., Metzler K.L., Borsos S., Chau J. Optimal killing of Streptococcus pneumoniae by gemifloxacin, levofloxacin and moxifloxacin. Novel Perspectives in Antibacterial Action 2002, 15-26. Royal Society of Medicine Press Limited, London. S.H. Gillespie, G.S. Tillotson (Eds.).
4. Blondeau J.M., Blondeau L.D., Hesje C., Borsos S. Application of two methods to determine killing of Streptococcus pneumoniae by various fluoroquinolones. J. Chemother. 2006, 18:366-372.
5. Blondeau J.M., Borsos S., Hesje C. Rate of methicillin-resistant Staphylococcus aureus (MRSA) eradication by fourth-generation fluoroquinolones at physiologically relevant concentrations. Association for Research in Vision and Ophthalmology 2009.
6. Blondeau J.M., Borsos S., Blondeau B.J. Killing of Staphylococcus pseudintermedius by enrofloxacin and its active metabolite ciprofloxacin using clinical relevant drug concentrations. American College of Veterinary Internal Medicine Forum (ACVIM) 2010.
7. Cester C.C., Toutain P.L. A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in dog. J. Pharm. Sci. 1997, 86:1148-1155.
8. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria isolated from animals: Approved Standard (M31-A3) 2008, Clinical and Laboratory Standards Institute, Wayne, PA.
9. Clinical and Laboratory Standards Institute Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically: Approved Standard (M07-A8) 2009, 8th ed.
10. Cole L.K., Papich M.G., Kwochkat K.W., Hillier A., Smeak D.D., Lehman A.M. Plasma and ear tissue concentrations of enrofloxacin and its metabolite ciprofloxacin in dogs with chronic end-stage otitis externa after intravenous administration of enrofloxacin. Vet. Dermatol. 2008, 20:51-59.
11. Dagan R., Klugman K.P., Craig W.A., Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J. Antimicrob. Chemother. 2001, 47:129-140.
12. Davis J.L., Foster D.M., Papich M. Pharmacokinetics and tissue distribution of enrofloxacin and its active metabolite ciprofloxacin in calves. J. Vet. Pharmacol. Ther. 2007, 30:564-571.
13. Eliopoulos G.M., Moellering R.C. Antimicrobial combinations. Antibiotics in Laboratory Medicine 1991, 432-492. The Williams and Wilkins Co., Baltimore, MA. V. Lorian (Ed.).
14. Grobbel M., Lubke-Becker A., Wieler L.H., Froyman R., Friederichs S., Filios S. Comparative quantification of the in vitro activity of veterinary fluoroquinolones. Vet. Microbiol. 2007, 124:73-81.
15. Hawkins E.C., Boothe D.M., Guinn A., Aucoin D., Ngyuen J. Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. J. Vet. Pharmacol. Ther. 1998, 21:18-23.
16. Hesje C., Blondeau J.M. Low propensity of gatifloxacin-BAK combination to select for fluoroquinolone resistance among methicillin-resistant Staphylococcus aureus. American Society of Cataract and Refractive Surgery (ASCRS) Symposium and Congress 2008.
17. Hesje C., Tillotson G.S., Blondeau J.M. MICs, MPCs and PK/PDs: a match (sometimes) made in hosts. Expert Rev. Respir. Med. 2007, 1:7-16.
18. Kung K., Riond J.L., Wanner M. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J. Vet. Pharmacol. Ther. 1993, 16:462-468.
19. Lautzenhiser S.J., Fialkowski J.P., Bjorling D., Rosin E. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs. Res. Vet. Sci. 2001, 70:239-241.
20. Marymont J.H., Marymont J. Laboratory evaluation of antibiotic combinations: a review of methods and problems. Lab. Med. 1981, 12:47-55.
21. Tyczkowska K., Hedeen K.M., Aucoin D., Aronson A.L. High performance liquid chromatographic method for the simultaneous determination of enrofloxacin and its primary metabolite ciprofloxacin in canine serum and prostatic tissue. J. Chromatogr. 1989, 493:337-346.
22. Wetzstein H.G. Comparative mutant prevention concentrations of pradofloxacin and other veterinary fluoroquinolones indicate differing potentials in preventing selection of resistance. Antimicrob. Agents Chemother. 2005, 49:4166-4173.